11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease

Bibliography

• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• ETXABE J, VAZQUEZ JA: Morbidity and mortality in Cushing's disease: an epidemiological approach. Chit. Endocrinol (1994) 40:479–484.
   PubMed Web of Science ®Google Scholar
• COLAO A, PIVONELLO R, SPIEZIA S et al: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Endocrinol Metab. (1999) 84:2664–2672.
   Google Scholar
• REUS VI, WOLKOWITZ OM: Antiglucocorticoid drugs in the treatment of depression. Expert Opin. Invest. Drugs (2001) 10:1789–1796.
   PubMed Web of Science ®Google Scholar
• BJORNTORP P, HOLM G, ROSMOND R: Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabetic Med. (1999) 16:373–381.
   PubMed Web of Science ®Google Scholar
• FILIPOVSKY J, DUCIMETIERE P, ESCHWEGE E, RICHARD JL, ROSSELIN G, CLAUDE JR: The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. Hypertens. (1996) 14:229–235.
   Web of Science ®Google Scholar
• WALKER BR, PHILLIPS DI, NOON JP et al: Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension (1998) 31:891–895.
   PubMed Web of Science ®Google Scholar
• FRASER R, INGRAM MC, ANDERSON NH, MORRISON C, DAVIES E, CONNELL JM: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension (1999) 33:1364–1368.
   PubMed Web of Science ®Google Scholar
• LUPIEN SJ, DE LEON M, DE SANTI S et al: Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat. Neurosci. (1998) 1:69–73.
   PubMed Web of Science ®Google Scholar
• WOLKOWITZ OM, REUS VI, CHAN T et al: Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol. Psych. (1999) 45:1070–1074.
   PubMed Web of Science ®Google Scholar
• GAILLARD RC, POFFET D, RIONDEL AM, SAURAT JH: RU486 inhibits peripheral effects of glucocorticoids in humans. Clin. Endocrinol Metab. (1985) 61:1009–1011.
   Google Scholar
• ELMORE SW, COGHLAN MJ, ANDERSON DD et al: Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H- [1] benzopyrano [3, 4-f]quinolines. Med. Chem. (2001) 44:4481–4491.
   Web of Science ®Google Scholar
• COGHLAN MJ, JACOBSON PB, LANE B et al.: A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol (2003) 17:860–869.
   PubMed Web of Science ®Google Scholar
• KYM PR, KORT ME, COGHLAN MJ et al.:Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-ally1-2,5-dihydro-2,2,4-trimethyl-lh-[1] benzopyrano [3,4-fIquinolines. [Med. Chem. (2003) 46:1016–1030.
   Web of Science ®Google Scholar
• EDGERTON D, SCOTT M, DOSS N et al.: A liver-selective glucocorticoid receptor antagonist (A-348441) inhibits net hepatic glucose output in the fasted dog. Diabetes (2003) 52\(Suppl. 1):A118. Abstract.
   Google Scholar
• STEWART PM, SHEPPARD MC: Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue specific enzymes. Mol Cell. Endocrinol (1992) 83:C13–C18.
   Web of Science ®Google Scholar
• SECKL JR, WALKER BR (Eds): Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism - Disorders of Steroid Metabolism. Bailliere Tindall, London (2001).
   Google Scholar
• AGARWAL AK, MUNE T, MONDER C, WHITE PC: NADH-dependent isoform of 1 113-hydroxysteroid dehydrogenase. Cloning and characterisation of cDNA from sheep kidney. J. Biol. Chem. (1994) 269:25959–25962.
   Google Scholar
• ALBISTON AL, OBEYESEKERE VR, SMITH RE, KROZOWSKI ZS: Cloning and tissue distribution of the human 1 113-hydroxysteroid dehydrogenase Type 2 enzyme. Mol Cell. Endocrinol (1994) 105:R11–R17.
   Web of Science ®Google Scholar
• STEWART PM, KROZOWSKI ZS: 1113-Hydroxysteroid dehydrogenase. Vitoria. Horm. (1999) 57:249–324.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the history of 11HSD research.
   Google Scholar
• WILSON RC, HARBISON MD, KROZOWSKI ZS et al: Several homozygous mutations in the gene for 1113-hydroxysteroid dehydrogenase Type 2 in patients with apparent mineralocorticoid excess. ./. Chu. Endocrinol Metab. (1995) 80:3145–3150.
   PubMed Web of Science ®Google Scholar
• MONDER C, STEWART PM, LAKSHMI V, VALENTINO R, BURT D, EDWARDS CR: Licorice inhibits corticosteroid 1113-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology (1989) 125:1046–1053.
   PubMed Web of Science ®Google Scholar
• KOTELEVTSEV YV, BROWN RW, FLEMING S, EDWARDS CR, SECKL JR, MULLINS JJ: Hypertension in mice caused by inactivation of 1 113-hydroxysteroid dehydrogenase Type 2. J. Clin. Invest. (1999) 103:683–689.
   PubMed Web of Science ®Google Scholar
• BROWN RW, DIAZ R, ROBS ON AC et al: The ontogeny of 1 113-hydroxysteroid dehydrogenase Type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology (1996) 137:794–797.
   PubMed Web of Science ®Google Scholar
• STEWART PM, ROGERSON FM, MASON JI: Type 2 1113-hydroxysteroid dehydrogenase messenger RNA and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal steroidogenesis. Chu. Endocrinol Metab. (1995) 80:885–890.
   PubMed Web of Science ®Google Scholar
• CHRISTY C, HADOKE PW, PATERSON JM, MULLINS JJ, SECKL JR, WALKER BR: Glucocorticoid action in mouse aorta; localisation of 1 113-hydroxysteroid dehydrogenase Type 2 and effects on responses to glucocorticoids in vitro. Hypertension (2003) 42:580–587.
   PubMed Web of Science ®Google Scholar
• YONG PYK, THONG KJ, ANDREW R, WALKER BR, HILLIER SG: Development-related increase in cortisol biosynthesis by human granulosa cells. Chu. Endocrinol Metab. (2000) 85:4728–4733.
   PubMed Web of Science ®Google Scholar
• AGARWAL AK, MONDER C, ECKSTEIN B, WHITE PC: Cloning and expression of rat cDNA encoding corticosteroid 1 113-dehydrogenase. J. Biol. Chem. (1989) 264:18939–18943.
   PubMed Web of Science ®Google Scholar
• SECKL JR, WALKER BR: Minireview: 1113-hydroxysteroid dehydrogenase Type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology (2001) 142:1371–1376.
   PubMed Web of Science ®Google Scholar
• •A short review laying out the key evidence in support of the role of 11HSD1 in modulating glucocorticoid receptor activation.
   Google Scholar
• LOW SC, CHAPMAN KE, EDWARDS CR, SECKL JR: liver-type 1113-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells. J. Mol Endocrinol (1994) 13:167–174.
   PubMed Web of Science ®Google Scholar
• BUJALSKA IJ, KUMAR S, STEWART PM: Does central obesity reflect 'Cushing's disease of the omentund? Lancet (1997) 349:1210–1213.
   PubMed Web of Science ®Google Scholar
• •This paper contained the original description of the predominant reductase activity of 11HSD1 in adipose tissue, and the hypothesis that this activity might be increased in obesity.
   Google Scholar
• JAMIESON PM, CHAPMAN KE, EDWARDS CR, SECKL JR: 1113-Hydroxysteroid dehydrogenase is an exclusive 1 113-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology (1995) 136:4754–4761.
   PubMed Web of Science ®Google Scholar
• RAJAN V, EDWARDS CR, SECKL JR: 1113-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 1 1-dehydrocorticosterone, potentiating neurotoxicity. Neurosci. (1996) 16:65–70.
   Web of Science ®Google Scholar
• ••This paper provided the first evidencethat 11HSD1 is a predominant reductase In the CNS and that its inhibition is potentially neuroprotective.
   Google Scholar
• JAMIESON PM, WALKER BR, CHAPMAN KE, ROSSITERS, SECKL JR: 1113-Hydroxysteroid dehydrogenase Type 1 is a predominant 11-reductase in the intact perfused rat liver. ./. Endocrinol (2000) 175:685–692.
   Google Scholar
• WALKER BR, CAMPBELL JC, FRASER R, STEWART PM, EDWARDS CR: Mineralocorticoid excess and inhibition of 1 113-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin. Endocrinol (Dxf.) (1992) 37:483–492.
   PubMed Web of Science ®Google Scholar
• KATZ JR, MOHAMED-ALI V, WOOD PJ, YUDKIN JS, COPPACK SW: An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin. Endocrinol (1999) 50:63–68.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DM, LAKSHMI V, MONDER C: Corticosteroid 1 113-dehydrogenase in rat testis. Endocrinology (1989) 125:209–216.
   PubMed Web of Science ®Google Scholar
• BUJALSKA IJ, WALKER EA, HEWISON M, STEWART PM: A switch in dehydrogenase to reductase activity of 1113-hydroxysteroid dehydrogenase Type 1 upon differentiation of human °mental adipose stromal cells. J. Clair Endocrinol Metab. (2002) 87:1205–1210.
   PubMed Web of Science ®Google Scholar
• DRAPER N, WALKER EA, BUJALSKA IJ et al: Mutations in the genes encoding 1 113-hydroxysteroid dehydrogenase Type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat. Genet. (2003) 34:434–439.
   PubMed Web of Science ®Google Scholar
• •The intriguing hypothesis that hexose-6-phosphate dehydrogenase (H6PDH) provides cofactor NADPH for 11HSD1 reductase is supported by this paper.
   Google Scholar
• MASER E, VOLKER B, FRIEBERTSHAUSER J: 1113-Hydroxysteroid dehydrogenase Type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry (2002) 41:2459–2465.
   PubMed Web of Science ®Google Scholar
• SHAFQAT N, ELLEBY B, SVENSSON S et al.: Comparative enzymology of 1 113-hydroxysteroid dehydrogenase Type 1 from glucocorticoid resistant (guinea pig) versus sensitive (human) species. ./. Biol. Chem. (2003) 278:2030–2035.
   PubMed Web of Science ®Google Scholar
• RABBITT EH, LAVERY GG, WALKER EA, COOPER MS, STEWART PM, HEWISON M: Prereceptor regulation of glucocorticoid action by 11 [131-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB J. (2002) 16:36–44.
   PubMed Web of Science ®Google Scholar
• BUJALSKA IJ, KUMAR S, HEWISON M, STEWART PM: Differentiation of adipose stromal cells: the roles of glucocorticoids and 1 113-hydroxysteroid dehydrogenase. Endocrinology (1999) 140:3188–3196.
   PubMed Web of Science ®Google Scholar
• YANG K, KHALIL MW, STRUTT BJ, KILLINGER DW: 1113-Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. J. Steroid Biochem. Mol. Biol. (1997) 60:247–253.
   PubMed Web of Science ®Google Scholar
• MASUZAKI H, PATERSON J, SHINYAMA H et al.: A transgenic model of visceral obesity and the metabolic syndrome. Science (2001) 294:2166–2170.
   PubMed Web of Science ®Google Scholar
• ••This paper supports the potent influence ofadipose 11HSD1 on obesity and features of the metabolic syndrome.
   Google Scholar
• PATERSON JM, HOLMES MC, MORTON NM, SECKL JR, MULLINS JJ: Liver-specific over-expression of 1113-HSD1 in transgenic mice produces insulin resistance, hyperlipidaemia and fatty liver. Proc. Endo. 2002(2002) P2-319. Abstract.
   Google Scholar
• KOTELEVTSEV YV, HOLMES MC, BURCHELL A et al.:1113-Hydroxysteroid dehydrogenase Type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress. Proc. Nati Acad. Sri. USA (1997) 94:14924–14929.
   PubMed Web of Science ®Google Scholar
• •This paper is the first in a series concerning 11HSD1 I- mice, and provides proof-of-principle that loss of 11HSD1 is beneficial for the features of the metabolic syndrome.
   Google Scholar
• HARRIS HJ, KOTELEVTSEV YV, MULLINS JJ, SECKL JR, HOLMES MC: 1113-Hydroxysteroid dehydrogenase Type 1 null mice have altered hypothalamic-pituitary-adrenal axis activity: a novel control of glucocorticoid feedback. Endocrinology (2001) 142:114–120.
   PubMed Web of Science ®Google Scholar
• MORTON NM, HOLMES MC, FIEVET C et al.: Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 1113-hydroxysteroid dehydrogenase Type 1 null mice. Biol Chem. (2001) 276:41293–41300.
   Web of Science ®Google Scholar
• MORTON NM, PATERSON JM, HOLMES MC, WALKER BR, MULLINS JJ, SECKL JR: 1113-Hydroxysteroid dehydrogenase Type 1 null mice resist dietary obesity and its metabolic complications. Proc. Endo. 2002 (2002) OR17-3. Abstract.
   Google Scholar
• MASUZAKI H, YAMAMOTO H, KENYON CJ et al.: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. (2003) 112:83–90.
   PubMed Web of Science ®Google Scholar
• •This paper shows the influence of adipose 11HSD1 on blood pressure, an effect apparently mediated by increased adipose angiotensinogen production. However, other studies in humans do not suggest that this mechanism is necessarily relevant in man.
   Google Scholar
• PATERSON JM, MORTON NM, HOLMES MC et al.: Metabolic syndrome without obesity: liver-specific overexpression of 1113-HSD1 in transgenic mice. Proc. Endo. 2003 (2003) OR39-4. Abstract.
   Google Scholar
• YAU JL, NOBLE JM, KENYON CJ etaL: Lack of tissue glucocorticoid reactivation in 1113- hydroxystero id dehydrogenase Type 1 knockout mice ameliorates age-related learning impairments. Proc. Nati Acad. Sri. USA (2001) 98:4716–4721.
   PubMed Web of Science ®Google Scholar
• ••This is a key paper in understanding theInfluence of 11HSD1 on cognitive function.
   Google Scholar
• RITCHIE K, TOUCHON J: Mild cognitive impairment: conceptual basis and current nosological status. Lancet (2000) 355:225–228.
   PubMed Web of Science ®Google Scholar
• LJUNG T, ANDERSSON B, BEN GTSSON B, BJORNTORP P, MARIN P: Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes. Res. (1996) 4:277–282.
   PubMedGoogle Scholar
• WALKER BR, SODERBERG S, LINDAHL B, OLSSON T: Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J. Intern Med. (2000) 247:198–204.
   PubMed Web of Science ®Google Scholar
• ROSMOND R, DALLMAN ME BJORNTORP P: Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities. J. Clin. Endocrinol. Metab. (1998) 83:1853–1859.
   PubMed Web of Science ®Google Scholar
• STRAIN GW, ZUMOFF B, STRAIN JJ, LEVIN J, FUKUSHIMA DK: Cortisol production in obesity. Metabolism (1980) 29:980–985.
   PubMed Web of Science ®Google Scholar
• LOTTENBERG SA, GIANNELLA-NETO D, DERENDORF H et al.: Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int.Pharmacol.Ther. (1998) 36:501–505.
   PubMed Web of Science ®Google Scholar
• ANDREW R, PHILLIPS DI, WALKER BR: Obesity and gender influence cortisol secretion and metabolism in marl. j. Cl/n. Endocrinol. Metab. (1998) 83:1806–1809.
   PubMed Web of Science ®Google Scholar
• REYNOLDS RIVI, WALKER BR, PHILLIPS DI et al.: Altered control of cortisol secretion in adult men with low birthweight and cardiovascular risk factors. Cl/n. Endocrinol. Metab. (2001) 86:245–250.
   PubMed Web of Science ®Google Scholar
• WALKER BR: How will we know if 1113-hydroxysteroid dehydrogenases are important in common diseases? Clin. Endocrinol. (Oxf.) (2000) 52:401–402.
   PubMed Web of Science ®Google Scholar
• STEWART PM, WALLACE AM, ATHERDEN SM, SHEARING CH, EDWARDS CR: Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 1113-hydroxysteroid dehydrogenase activity in man. Clin. Sri. (1990) 78:49–54.
   Google Scholar
• RASK E, WALKER BR, SODERBERG S et al.: Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 1 113-hydroxysteroid dehydrogenase Type 1 activity. Clin. Endocrinol. Metab. (2002) 87:3330–3336.
   Google Scholar
• TIOSANO D, EISENTEIN I, MILITIANU D, CHROUSOS GP, HOCHBERG Z: 1113-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J. Clin. Endocrinol. Metab. (2003) 88:379–384.
   PubMed Web of Science ®Google Scholar
• STEWART PM, BOULTON A, KUMAR S, CLARK PM, SHACKLETON CH: Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J. Cl/n. Endocrinol Metab. (1999) 84:1022–1027.
   PubMed Web of Science ®Google Scholar
• RASK E, OLSSON T, SODERBERG S et al.: Tissue-specific dysregulation of cortisol metabolism in human obesity. Clin. Endocrinol. Metab. (2001) 86:1418–1421.
   Google Scholar
• ••This is the first in a series of papersdocumenting increased subcutaneous adipose 11HSD1 in human obesity.
   Google Scholar
• WESTERBACKA J, YKI-JARVINEN H, VEHKAVAARA S et al.: Body fat distribution and cortisol metabolism in healthy men: enhanced 513-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. Clin. Endocrinol Metab. (2003) 88:4924–4931.
   Google Scholar
• LIVINGSTONE DE, JONES GC, SMITH K, ANDREW R, KENYON CJ, WALKER BR: Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology (2000) 141:560–563.
   PubMed Web of Science ®Google Scholar
• PAULMYER-LACROIX O, BOULLU S, OLIVER C, ALESSI MC, GRINO M: Expression of the mRNA coding for 1 113-hydroxysteroid dehydrogenase Type 1 in adipose tissue from obese patients: an in situ hybridization study. Endocrinol Metab. (2002) 87:2701–2705.
   Google Scholar
• LINDSAY RS, WAKE DJ, NAIR S et al:Subcutaneous adipose 1113-hydroxysteroid dehydrogenase Type 1 activity and mRNA levels are associated with adiposity and insulinaemia in Pima Indians and Caucasians. I Clin. Endocrinol. Metab. (2003) 88:2738–2744.
   PubMed Web of Science ®Google Scholar
• WAKE DJ, RASK E, LIVINGSTONE DE, SODERBERG S, OLSSON T, WALKER BR: Local and systemic impact of transcriptional upregulation of 1 113-hydroxysteroid dehydrogenase Type 1 in adipose tissue in human obesity. Endocrinol Metab. (2003) 88:2983–2988.
   Google Scholar
• TOMLINSON JW, SINHA B, BUJALSKA I, HEWISON M, STEWART PM: Expression of 1 113- hydroxysteroid dehydrogenase Type 1 in adipose tissue is not increased in human obesity../. Clin. Endocrinol Metab. (2002) 87:5630–5635.
   PubMed Web of Science ®Google Scholar
• PHILLIPOU G, PALERMO M, SHACKLETON CH: Apparent cortisone reductase deficiency: a unique form of hypercortisolism. I Clin. Endocrinol Metab. (1996) 81:3855–3860.
   PubMed Web of Science ®Google Scholar
• JAMIESON A, WALLACE AM, WALKER BR et al.: Apparent cortisone reductase deficiency: a functional defect in 1 113-hydroxysteroid dehydrogenase Type 1. Endocrinol Metab. (1999) 84:3570–3574.
   Google Scholar
• TOMLINSON JW, MOORE J, COOPER MS et al: Regulation of expression of 1 113-hydroxysteroid dehydrogenase Type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology (2001) 142: 1982-1989.
   Google Scholar
• LIU Y, NAKAGAWA Y, WANG Y et al: Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes (2003) 52:1409–1416.
   PubMed Web of Science ®Google Scholar
• ANDREWS RC, HERLIHY O, LIVINGSTONE DE, ANDREW R, WALKER BR: Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. I Chit. Endocrinol Metab. (2002) 87:5587–5593.
   PubMed Web of Science ®Google Scholar
• DRAPER N, ECHWALD SM, LAVERY GG et al.: Association studies between microsatellite markers within the gene encoding human 1 113-hydroxysteroid dehydrogenase Type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. I Clin. Endocrinol Metab. (2002) 87:4984–4990.
   PubMed Web of Science ®Google Scholar
• STEWART PM, VALENTINO R, WALLACE AM, BURT D, SHACKLETON CH, EDWARDS CR: Mineralocorticoid activity of liquorice: 1 113-hydroxysteroid dehydrogenase deficiency comes of age. Lancet (1987) 2:821–824.
   PubMed Web of Science ®Google Scholar
• TEELUCKSINGH S, BENEDIKTSSON R, LINDSAY RS et al.: Liquorice. Lancet (1991) 337:1549.
   PubMed Web of Science ®Google Scholar
• LATIF SA, CONCA TJ, MORRIS DJ: The effects of the liquorice derivative, glycyrrhetinic acid, on hepatic 3a- and 313-hydroxysteroid dehydrogenases and 5a- and 513-reductase pathways of metabolism of aldosterone in male rats. Steroids (1990) 55:52–58.
   PubMedGoogle Scholar
• ULLIAN ME, HAZEN-MARTIN DJ, WALSH LG, DAVDA RK, EGAN BM: Carbenoxolone damages endothelium and enhances vasoconstrictor action in aortic rings. Hypertension (1996) 27:1346–1352.
   PubMed Web of Science ®Google Scholar
• COLEMAN HA, TARE M, PARKINGTON HC: K+ currents underlying the action of endothelium-derived hyperpolarizing factor in guinea-pig, rat and human blood vessels. Physiol. (fond) (2001) 531:359–373.
   PubMed Web of Science ®Google Scholar
• TARE M, COLEMAN HA, PARKINGTON HC: Glycyrrhetinic derivatives inhibit hyperpolarization in endothelial cells of guinea pig and rat arteries. Am. Physiol. Heart Circ. Physiol. (2002) 282:H335–H341.
   Web of Science ®Google Scholar
• KENNY LC, BAKER PN, KENDALL DA,RANDALL MD, DUNN WR: The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. BE Pharmacol. (2002) 136:1085–1088.
   Google Scholar
• GOTO K, FUJII K, KANSUI Y, ABE I, IIDA M: Critical role of gap junctions in endothelium-dependent hyperpolarization in rat mesenteric arteries. Clin. Exp. Pharmacol. Physiol. (2002) 29:595–602.
   PubMed Web of Science ®Google Scholar
• CHAYTOR AT, MARSH WL, HUTCHESON IR, GRIFFITH TM: Comparison of glycyrrhetinic acid isoforms and carbenoxolone as inhibitors of EDHF-type relaxations mediated via gap junctions. Endothelium (2000) 7:265–278.
   PubMed Web of Science ®Google Scholar
• WALKER BR, CONNACHER AA, LINDSAY RM, WEBB DJ, EDWARDS CR: Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 1 1-oxosteroid reductase in enhancing glucocorticoid receptor activation. ./. Clin. Endocrinol. Metab. (1995) 80:3155–3159.
   PubMed Web of Science ®Google Scholar
• •This is a key paper from which much of the authors' further work originated. The data showed that inhibition of 11HSD1 enhanced 'whole body' insulin sensitivity, an effect confirmed by later studies as being mediated by enhanced hepatic insulin sensitivity.
   Google Scholar
• ANDREWS RC, ROOYACKERS O, WALKER BR: Effects of the 1 113-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with Type 2 diabetes. I Clin. Endocrinol. Metab. (2003) 88:285–291.
   PubMed Web of Science ®Google Scholar
• LIVINGSTONE DE, WALKER BR: Is 1113-hydroxysteroid dehydrogenase Type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Marmara Exp. Ther. (2003) 305:167–172.
   PubMed Web of Science ®Google Scholar
• JELLINCK PH, MONDER C, MCEWEN BS, SAKAI RR: Differential inhibition of 1113-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. I Steroid Biochem. Mol. Biol. (1993) 46:209–213.
   PubMed Web of Science ®Google Scholar
• SANDEEP TC, MACLULLICH AM, YAU JL et al.:1113-Hydroxysteroid dehydrogenase Type 1 is expressed in human brain: inhibition with carbenoxolone improves cognitive function in healthy elderly men. Endocr. Abstr. (2002) 3:0C41. Abstract.
   Google Scholar
• BARF T, VALLGARDA J, EMOND R et al.: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 1113-hydroxysteroid dehydrogenase Type 1. J. Med. Chem. (2002) 45:3813–3815.
   Google Scholar
• ALBERTS P, ENGBLOM L, EDLING N et al: Selective inhibition of 1113-hydroxysteroid dehydrogenase Type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia (2002) 45:1528–1532.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the metabolic benefitsof the first 11ESD1-selectiye inhibitors, the arylsulphonamidothiazoles, in mice.
   Google Scholar
• HUNDERTMARK S, DILL A, EBERT A et al: Foetal lung maturation in 1113-hydroxysteroid dehydrogenase Type 1 knockout mice. Horm. Metab. Res. (2002) 34:545–549.
   PubMed Web of Science ®Google Scholar
• HUNDERTMARK S, DILL A, BUHLER H et al.: 1113-hydroxysteroid dehydrogenase Type 1: a new regulator of fetal lung maturation. Horm. Metab. Res. (2002) 34:537–544.
   PubMed Web of Science ®Google Scholar
• HAD OKE PW, CHRISTY C, KOTELEVTSEV YV et al.: Endothelial cell dysfunction in mice after transgenic knockout of Type 2, but not Type 1, 1113-hydroxysteroid dehydrogenase. Circulation (2001) 104:2832–2837.
   PubMed Web of Science ®Google Scholar
• COOPER MS, BUJALSKA I, RABBITT E, WALKER EA, BLAND R, SHEPPARD MC: Modulation of 11 [131-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Bone !Winer. Res. (2001) 16:1037–1044.
   PubMed Web of Science ®Google Scholar
• COOPER MS, RABBITT EH, GODDARD PE, BARTLETT WA, HEWISON M, STEWART PM: Osteoblastic 11 13-hydroxysteroid dehydrogenase Type 1 activity increases with age and glucocorticoid exposure. Bone Miner Res. (2002) 17:979–986.
   PubMed Web of Science ®Google Scholar
• THIERINGER R, LE GRAND CB, CARBIN L, CAI TQ, WONG B, WRIGHT SD: 11[131-Hydroxysteroid dehydrogenase Type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol (2001) 167:30–35.
   PubMed Web of Science ®Google Scholar
• EVAGELATOU M, PETERSON SL, COOKE BA: Leukocytes modulate 11(3-hydroxysteroid dehydrogenase (1113-HSD) activity in human granulosa-lutein cell cultures. Mol Cell. Endocrinol (1997) 133:81–88.
   PubMed Web of Science ®Google Scholar
• TETSUKA M, HAINES LC, MILNE M, SIMPSON GE, HILLIER SG: Regulation of 11(3-hydroxysteroid dehydrogenase Type 1 gene expression by LH and interleukin-1(3 in cultured rat granulosa cells. J. Endocrinol (1999) 163:417–423.
   PubMed Web of Science ®Google Scholar
• CAI TQ, WONG B, MUNDT SS, THIERINGER R, WRIGHT SD: Induction of 11 [131-hydroxysteroid dehydrogenase Type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J. Steroid Biochem. Mol Biol. (2001) 77:117–122.
   PubMed Web of Science ®Google Scholar
• SOUNESS GW, LATIF SA, LAURENZO JL, MORRIS DJ: 11 a- and 11(3-hydroxyprogesterone, potent inhibitors of 11(3-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. Endocrinology (1995) 136: 1809-1812.
   Google Scholar
• BREM AS, BINA RB, KING T, MORRIS DJ: 11130H-progesterone affects vascular glucocorticoid metabolism and contractile response. Hypertension (1997) 30:449–454.
   PubMed Web of Science ®Google Scholar
• MORITA H, ZHOU M, FOECKING MF et al.:1113-Hydroxysteroid dehydrogenase Type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: specific inhibition by 11a-hydroxyprogesterone. Endocrinology (1996) 137:2308–2314.
   PubMed Web of Science ®Google Scholar
• SHIMOYAMA Y, HIRABAYASHI K, MATSUMOTO H, SATO T, SHIBATA S, INOUE H: Effects of glycyrrhetinic acid derivatives on hepatic and renal 11(3-hydroxysteroid dehydrogenase activities in rats. J. Pharm. Pharmacol (2003) 55:811–817.
   PubMed Web of Science ®Google Scholar
• KATO H, KANAOKA M, YANO S, KOBAYASHI M: 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. j Cl/n. Endocrinol Metab. (1995) 80:1929–1933.
   PubMed Web of Science ®Google Scholar
• MORRIS DJ, SEMAFUKO WE, LATIF SA, VOGEL B, GRIMES C, SHEFF MF: Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension (1992) 20:356–360.
   PubMed Web of Science ®Google Scholar
• LATIF SA, HARTMAN LR, SOUNESS GW, MORRIS DJ: Possible endogenous regulators of steroid inactivating enzymes and glucocorticoid-induced Na + retention. Steroids (1994) 59:352–356.
   PubMed Web of Science ®Google Scholar
• SEMAFUKO WE, SHEFF ME GRIMES CA et al: Inhibitors of 11(3-hydroxysteroid dehydrogenase and 513-steroid reductase in urine from patients with congestive heart failure. Ann. Cl/n. Lab. Sci. (1993) 23:456–461.
   PubMed Web of Science ®Google Scholar
• WALKER BR, AGGARWAL I, STEWART PM, PADFIELD PL, EDWARDS CR: Endogenous inhibitors of 1113-hydroxysteroid dehydrogenase in hypertension. J. Clin. Endocrinol Metab. (1995) 80:529–533.
   PubMed Web of Science ®Google Scholar
• WALKER BR, WILLIAMSON PM, BROWN MA, HONOUR JW, EDWARDS CR, WHIT WORTH JA: 1113-Hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy. Hypertension (1995) 25:626–630.
   PubMed Web of Science ®Google Scholar
• TAKEDA Y, MIYAMORI I, IKI K et al: Endogenous renal 1113-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension (1996) 27:197–201.
   PubMed Web of Science ®Google Scholar
• ROSEBOOM TJ, VAN DER MEULEN JP, RAVELLI AJ et al: Blood pressure in adults after prenatal exposure to famine. Hypertens. (1999) 17:325–330.
   Web of Science ®Google Scholar
• LATIF SA, SHEFF ME RIBEIRO CE, MORRIS DJ: Selective inhibition of sheep kidney 1113-hydroxysteroid dehydrogenase isoform 2 activity by 5a-reduced (but not V) derivatives of adrenocorticosteroids. Steroids (1997) 62:230–237.
   PubMed Web of Science ®Google Scholar
• THURSTON LM, JONAS KC, ABAYASEKARA DR, MICHAEL AE: Ovarian modulators of 1113-hydroxysteroid dehydrogenase (11,RHSD) activity in follicular fluid from bovine and porcine large antral follicles and spontaneous ovarian cysts. Biol. Reprod. (2003) 68:2157–2163.
   PubMed Web of Science ®Google Scholar
• BUHLER H, PERSCHEL FH, HIERHOLZER K: Inhibition of rat renal 1113-hydroxysteroid dehydrogenase by steroidal compounds and triterpenoids; structure/function relationship. 13iochim. Biophys. Acta (1991)1075:206–212.
   PubMed Web of Science ®Google Scholar
• STAUFFER AT, ROCHAT MK, DICK B, FREY FJ, ODERMATT A: Chenodeoxycholic acid and deoxycholic acid inhibit 1113-hydroxysteroid dehydrogenase Type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J. Biol. Chem. (2002) 277:26286–26292.
   PubMed Web of Science ®Google Scholar
• PERSCHEL FH, BUHLER H, HIERHOLZER K: Bile acids and their amidates inhibit 1113-hydroxysteroid dehydrogenase obtained from rat kidney. PITugers Arch. (1991) 418:538–543.
   PubMed Web of Science ®Google Scholar
• ESCHER G, NAWROCKI A, STAUB T et al.: Down-regulation of hepatic and renal 1 113-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology (1998) 114:175–184.
   PubMed Web of Science ®Google Scholar
• HOMMA M, OKA K, NIITSUMA T, ITOH H: A novel 1113-hydroxysteroid dehydrogenase inhibitor contained in Saiboku-To, a herbal remedy for steroid-dependent bronchial asthma. Phann. Pharmacol (1994) 46:305–309.
   PubMed Web of Science ®Google Scholar
• HOMMA M, OKA K, IKESHIMA K et al.: Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ./. Phann. Pharmacol (1995) 47:687–692.
   PubMed Web of Science ®Google Scholar
• SONG D, LORENZO B, REIDENBERG MM: Inhibition of 1 113-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J. Lab. Clin. Med. (1992) 120:792–797.
   PubMed Web of Science ®Google Scholar
• WANG MS, LORENZO JB, REIDENBERG MM: NAD- and NADP-dependent 1113-hydroxysteroid dehydrogenase isoforms in guinea pig kidney with gossypol inhibition. Acta Pharm. Sin. (1997) 18:481–485.
   Web of Science ®Google Scholar
• RAVEN PW, CHECKLEY SA, TAYLOR NF: Extra-adrenal effects of metyrapone include inhibition of the 1 1-oxoreductase activity of 1 13-hydroxysteroid dehydrogenase:a model for 11-HSD I deficiency. Endocrinol (Ox1) (1995) 43:637–644.
   Google Scholar
• THOMSON LM, RAVEN PW, SMITH KE, HINSON JP: Effects of metyrapone on hepatic cortisone-cortisol conversion in the rat. Endocr. Res. (1998) 24:607–611.
   PubMed Web of Science ®Google Scholar
• SAMPATH-KUMAR R, YU M, KHALIL MW, YANG K: Metyrapone is a competitive inhibitor of 1 13-hydroxysteroid dehydrogenase Type 1 reductase. I Steroid Biochern. Mol Biol. (1997) 62:195–199.
   PubMed Web of Science ®Google Scholar
• FUSTER D, ESCHER G, VOGT B et al: Furosemide inhibits 113-hydroxysteroid dehydrogenase Type 2. Endocrinology (1998) 139:3849–3854.
   PubMed Web of Science ®Google Scholar
• ESCHER G, MEYER KV, VISHWANATH BS, FREY BM, FREY FJ: Furosemide inhibits 113-hydroxysteroid dehydrogenase in vitro and in vivo. Endocrinology (1995) 136: 1759-1765.
   Google Scholar
• LEE YS, LORENZO BJ, KOUFIS T, REIDENBERG MM: Grapefruit juice and its flavonoids inhibit 113-hydroxysteroid dehydrogenase. Clin. Phannacol Ther. (1996) 59:62–71.
   PubMed Web of Science ®Google Scholar
• ZHANG YD, LORENZO B, REIDENBERG MM: Inhibition of 113-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compound. I Steroid Biochern Mol. Biol. (1994) 49:81–85.
   PubMed Web of Science ®Google Scholar
• PALERMO M, ARMANINI D, SHACKLETON CH et al.: Furosemide and 1 13-hydroxysteroid dehydrogenase activity, in man. Exp. Chit. Endocrinol Diabetes (2002) 110:272–276.
   PubMed Web of Science ®Google Scholar
• ZHANG YD, WANG MS: Inhibition of 1 13-hydroxysteroid dehydrogenase obtained from guinea pig kidney by some bioflavonoids and triterpenoids. Acta Pharm. Sin. (1997) 18:240–244.
   PubMed Web of Science ®Google Scholar
• PALERMO M, ARMANINI D, DELITALA G: Grapefruit juice inhibits 1113-hydroxysteroid dehydrogenase in vivo, in man. Clin. Endocrinol (Dxf) (2003) 59:143–144.
   PubMed Web of Science ®Google Scholar